⌕
Johnson & Johnson · JNJ · NYSE
Tenet 48 · Mixed
Compare
$282.55−1.12%At closeTenet 48 · Mixed
$282.55−3.20 (−1.12%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$282.70+0.15 (+0.05%)
After hours: Nov 16, 2026, 6:02 PM ET

Johnson & Johnson (JNJ) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 16, 2026 · 11:36 ETEARNINGS EXPECTED BY JAN 25
J&J Stock Rallies More Than 10% in a Month: Time to Buy, Sell or Hold?

JNJ's rally reflects stronger earnings and promising drug launches, but MedTech weakness, patent losses and litigation risks remain.…

● WSJNov 16, 2026 · 08:37 ET
Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion

Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.…

● Business WireNov 16, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (“Ollin”) a clinical-stage biopharmaceutical company deve…

● Defense WorldNov 14, 2026 · 04:41 ETEARNINGS EXPECTED BY JAN 25
Johnson & Johnson $JNJ Shares Newly Purchased by AlpenGlobal Capital LLC

AlpenGlobal Capital LLC acquired a new stake in Johnson and Johnson (NYSE: JNJ) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acq…

● Defense WorldNov 13, 2026 · 03:57 ETEARNINGS EXPECTED BY JAN 25
2,825 Johnson & Johnson $JNJ Shares Sold by Barr E S & Co.

Barr E S and Co. lessened its position in Johnson and Johnson (NYSE: JNJ) by 2.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fun…

● Schwab NetworkNov 12, 2026 · 13:00 ET
The Big 3: JNJ, LLY, AAPL

Amid the broader tech sell-off following Nvidia (NVDA) CEO Jensen Huang's resignation, Dan Deming looks to healthcare and “anti-AI” plays for stability. He says he's following the momentum in stocks including Johnson & J…

● Zacks Investment ResearchNov 12, 2026 · 12:31 ETEARNINGS EXPECTED BY JAN 25
Johnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?…

● PRNewsWireNov 12, 2026 · 10:40 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ).  Such investors are advised to contact Danielle Peyton at ne…

● The Motley FoolNov 11, 2026 · 15:00 ET
Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?

Johnson & Johnson maintains a massive healthcare presence across both innovative medicines and advanced medical technologies. Eli Lilly is currently defined by explosive growth in the metabolic health market, particularl…

● The Motley FoolNov 11, 2026 · 14:57 ET
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?

Johnson & Johnson is expertly handling a recent major patent cliff. Recent launches should help boost sales growth over the next few years.…

● Business WireNov 11, 2026 · 11:36 ET
Massachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case

DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a verdict in the amount of $1,914,990 accompanied by court ordered interest of $1,410,541 for a sum total of $3,3…

● 247 WallstNov 11, 2026 · 10:17 ET
SGOV Yields 3.63%. Can Johnson & Johnson or Verizon Pay Retirees More?

One income stream resets every time the Fed moves, while two others depend on a board's vote and a balance sheet. Which payout holds up best over a long retirement, and why might taxes change the answer?…

● Business WireNov 10, 2026 · 09:00 ET
Dean Omar Branham Shirley Secures $3,325,000 Verdict Against Johnson & Johnson in Mesothelioma Case

DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a $3,325,000 jury verdict against Johnson & Johnson on behalf of the family of Winifred “Missy” Haddad, a Massach…

● PRNewsWireNov 10, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study

CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studies Two positive Phase 3 studies will support a …

● PRNewsWireNov 8, 2026 · 11:00 ETCOMPANY'S OWN WORDS
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer

First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against cancer Deep and susta…

● PRNewsWireNov 7, 2026 · 10:03 ETCOMPANY'S OWN WORDS
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide

Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at We…

● PRNewsWireNov 7, 2026 · 10:03 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 25
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients

New patient experience data a to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 stud…

● PRNewsWireNov 5, 2026 · 21:27 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newa…

Expected by Jan 25. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just JNJ · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.